Boehringer Ingelheim announced this week its intent to join The Leukemia and Lymphoma Society's (LLS) Beat AML initiative, which aims to advance treatments for patients with acute myeloid leukemia (AML).
"Beat AML demonstrates The Leukemia and Lymphoma Society's ability to convene medical and research communities, including biopharmaceutical companies like Boehringer Ingelheim, to think and act boldly in the quest for new and better treatments for blood cancer patients," Dr. Louis DeGennaro, LLS president and CEO, said. "Our aim is to accelerate the rate at which precisely targeted breakthrough therapies reach patients who urgently need them."
Beat AML, a collaborative trial program, will evaluate medicines from several biopharmaceutical companies and will enroll newly diagnosed patients who will be assigned to a treatment arm based on genomic analysis. For its part, Boehringer Ingelheim will provide a potential treatment for one arm of the trial: the company's investigational anti-CD33 monoclonal antibody, BI 836858.
"This is a unique opportunity to put the interests of a particularly underserved patient population front and center by bringing multiple biopharmaceutical companies with investigational medicines targeting AML together," Dr. Martina Flammer, vice president of clinical development at Boehringer Ingelheim, said. "Boehringer Ingelheim is proud to join other leading experts and medical centers to take part in this pioneering initiative."
